WHO ICTRP trial
Using the blood pressure medication losartan to improve outcomes for patients…
ISRCTN48734830 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN48734830 |
|---|---|
| Public title | Using the blood pressure medication losartan to improve outcomes for patients with SARS CoV-2 |
| Scientific title | RAAS blockagE in SARS COV-2 Critically ill patiEnts– a Randomized controlled trial |
| Primary sponsor | Stockholm South General Hospital |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | Sweden |
| Conditions | COVID-19 (SARS-CoV-2 infection) Infections and Infestations |
| Interventions | Patients in the active arm of the trial will be receiving open-label Losartan in a dosage titrated with regards to blood pressure and renal function up to a maximum of 100 mg once daily. Active treatment with Losartan will continue until… |
| Registration date | Oct 7, 2020 |
| Target size | 750 |
| Secondary IDs | 2020-002040-22;Nil known;Nil known |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: